Abstract
Background & Aims: Delayed diagnosis of inflammatory bowel disease (IBD) leads to prolonged symptoms and worse long-term outcomes. We sought to evaluate whether race, ethnicity, disease type, and social factors are associated with delayed diagnosis of pediatric IBD. Methods: We performed a cross-sectional study of newly diagnosed pediatric patients with IBD at 22 United States sites from 2019 to 2022. Parents/guardians reported race, ethnicity, time between symptom onset and diagnosis, and other social determinants of health. Through bivariate and multivariable analyses using generalized estimating equations, we evaluated associations between these factors and diagnosis time defined as ≤60 days, 61 to 180 days, 181 to 365 days, and >365 days. Results: We enrolled 869 participants (mean age at diagnosis, 13.1 years; 52% male; 57% Crohn's disease [CD]; 34% ulcerative colitis [UC]; 8% Hispanic; 30% non-White). Overall, the mean time to diagnosis was 265.9 days. After adjustment, factors associated with longer diagnosis time included CD vs UC (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.9–3.5), 2 or more other health conditions (OR, 1.7; 95% CI, 1.1–2.7), and longer travel time to clinic (>1 hour [OR, 1.7; 95% CI, 1.2–2.4], >2 hours (OR, 1.8; 95% CI, 1.2–2.9] each vs <30 minutes). There was no association with race, ethnicity, birth country, gender, parent education, household income, insurance type, health literacy, and health system distrust. Conclusions: Consistent with prior literature, diagnostic delay is longer for CD than UC. Reassuringly, time to diagnosis is equitable across racioethnic groups. New models of diagnostic care are needed for communities affected by longer travel times.
Original language | English (US) |
---|---|
Pages (from-to) | 825-834 |
Number of pages | 10 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 23 |
Issue number | 5 |
DOIs | |
State | Published - Apr 2025 |
Funding
Funding This research was funded by Centers for Disease Control and Prevention (CDC) grant 1U01DP006369. Conflicts of interest These authors disclose the following: Shehzad Saeed served on the advisory board and speakers bureau for Abbvie, Inc. Sofia G. Verstraete serves as Principal Investigator or Sub Investigator for trials with Celgene, Lilly, Genentech, Regeneron, Pfizer, and Abbvie. Jeremy Adler reports research funding from Janssen Research & Development \u2013 not relevant to this study. The remaining authors disclose no conflicts. Funding This research was funded by Centers for Disease Control and Prevention (CDC) grant 1U01DP006369 .
Keywords
- Crohn's Disease
- Diagnostic Delay
- Disparities
- Health Equity
- Race
- Ulcerative Colitis
ASJC Scopus subject areas
- Hepatology
- Gastroenterology